Study evaluates antibiotic treatment in Alzheimer's | Drug promising in treating tumors with gene fusions in youths | Dabigatran may not curb post-cryptogenic stroke recurrence
May 17, 2019
CONNECT WITH SNMMI LinkedInFacebookTwitterYoutube
SNMMI SmartBrief
News for nuclear medicine and molecular imaging professionals
SIGN UP ⋅   FORWARD
Top Story
Study evaluates antibiotic treatment in Alzheimer's
Researchers at the University of Chicago found that male mouse models with Alzheimer's disease that received long-term antibiotic treatment had gut microbiome changes resulting in reduced amyloid plaque buildup and microglial activation. However, the findings in the Journal of Experimental Medicine showed gut microbiome changes prompting increased inflammation and microglial activation among female mice that were given the antibiotic cocktail.
ScienceDaily/News release (5/16) 
LinkedIn Twitter Facebook Email
Clinical News & Research
Drug promising in treating tumors with gene fusions in youths
All children with tumors that have ALK, ROS1 or NTRK1/2/3 gene fusions or ALK mutations who received entrectinib, an investigational tyrosine kinase inhibitor, had "rapid and durable" treatment response, according to a study to be presented at the American Society of Clinical Oncology's annual meeting. "Although the target fusions are rare and the chances of finding the fusion may be low, clinicians should be looking for these gene aberrations because the impact of therapy is very promising -- especially when alternative treatment options are limited," said researcher Dr. Giles Robinson.
Healio (free registration)/HemOnc Today (5/16) 
LinkedIn Twitter Facebook Email
Dabigatran may not curb post-cryptogenic stroke recurrence
Individuals with recent embolic stroke of an unknown source who received dabigatran had similar rates of recurrent strokes and ischemic strokes, compared with those who were given aspirin, researchers reported in The New England Journal of Medicine. The findings also showed similar odds of major bleeding in both groups, but clinically relevant minor bleeds were more prevalent among those in the dabigatran group.
MedPage Today (free registration) (5/16) 
LinkedIn Twitter Facebook Email
Study: Low-fat diet may reduce breast cancer mortality risk
Follow-up data from the Women's Health Initiative that spanned almost 20 years showed women who ate a low-fat diet were 21% less likely to die from breast cancer, compared with those who followed a more typical high-fat diet, researchers said at an American Society of Clinical Oncology briefing ahead of the group's annual meeting. Of the women who did develop breast cancer, those who ate a low-fat diet had a 15% reduced risk of dying from any cause.
MedPage Today (free registration) (5/15) 
LinkedIn Twitter Facebook Email
Industry Report
SHINE Medical gets exclusive license for Lu-177 production method
SHINE Medical Technologies and the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences have entered an intellectual property license agreement granting SHINE exclusive license to a technique used to facilitate rare earth element separation for lutetium-177 production.
AuntMinnie (free registration) (5/16) 
LinkedIn Twitter Facebook Email
MorphoSys reports positive data from DLBCL candidate's midstage trial
MorphoSys announced the completion of its midstage trial that assessed its lead candidate, MOR208, in combination with Celgene's Revlimid, or lenalidomide, as a treatment for patients who have relapsed or refractory diffuse large B cell lymphoma and are not eligible for autologous stem cell transplantation and high-dose chemotherapy. Data show the study achieved its primary endpoint, with a 60% objective response rate among the 80 participants and a complete response rate of 43%.
Seeking Alpha (5/16) 
LinkedIn Twitter Facebook Email
News from the Field
Report highlights factors hindering improvements in patient matching
Researchers from The Pew Charitable Trusts and the Massachusetts eHealth Collaborative interviewed health care executives and experts and found that all of the respondents agreed that patient matching rates for an effective health data exchange aren't where they want them, which could lead to patient safety issues and delays in care. When asked about the impediments to improved patient matching, respondents cited a lack of data standards and perceived costs of solutions, and a majority of participants said creating a unique patient identifier could help address cost issues.
Health IT Analytics (5/15) 
LinkedIn Twitter Facebook Email
Health Policy
Efforts to bolster ACA might sink drug pricing bills
House Democrats included language shoring up the Affordable Care Act in bills meant to manage drug prices, which might doom the bills in the Republican-controlled Senate.
Politico (5/16) 
LinkedIn Twitter Facebook Email
Grants and Funding
New approaches to cancer block evolution
The UK's Institute of Cancer Research is investing around $96.5 million in the new Center for Cancer Drug Discovery, where scientists will take an evolutionary approach to controlling cancer. One path is based on evolutionary herding, or forcing cancer cells to change in a way that makes them vulnerable to the next treatment; the other blocks the action of APOBEC proteins in the immune system to prevent cancer from evolving and becoming resistant to treatment.
Reuters (5/15) 
LinkedIn Twitter Facebook Email
Advancing Health Care
How physician practices can protect against cyber threats
Practices of all sizes are at risk from cyber threats, but carefully reviewing cyber vulnerabilities can help reduce the chances of falling prey to them. One often-overlooked precaution is training staff members on how to spot suspicious links and communications.
Modern Medicine/Medical Economics (5/15) 
LinkedIn Twitter Facebook Email
From SNMMI
Watch the JNM Podcast!
Watch the JNM Podcast on YouTube for short video briefings on JNM's featured articles. In the most recent podcast, Drs. Matthias Brendel and Carola Focke discuss research showing a way to better predict progression of Alzheimer's disease, and Dr. Irene Virgolini discusses a 12-year study of patients who received peptide receptor radionuclide therapy for malignant neuroendocrine tumors. Watch the podcast.
LinkedIn Twitter Facebook Email
Register for the fifth-annual Hot Trot 5K Run/Walk at the SNMMI Annual Meeting
Registration is open for the fifth-annual "Hot Trot 5K" run/walk, taking place at the SNMMI 2019 Annual Meeting. Proceeds benefit the SNMMI-TS Professional Development and Education Fund. A portion of registration proceeds will also support Project Access, providing low-income families with the tools needed to break the cycle of poverty. Learn more.
LinkedIn Twitter Facebook Email
Display images to show real-time content
Learn more about SNMMI:
SNMMI | Join/Renew Your Membership | MySNMMI | Meetings
Education | News & Publications | Advocacy | Donate
  
  
Give credit where credit is due: simply said, if you want loyalty and best effort, you must be thoughtful.
Estee Lauder,
businesswoman

May is Jewish American Heritage Month

LinkedIn Twitter Facebook Email
  
  
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Doug Harris
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2019 SmartBrief, Inc.®
Privacy Policy (updated May 25, 2018) |  Legal Information